Wellmune and Biothera’s other patented ingredients are derived from a proprietary strain of yeast (Saccharomyces cerevisiae). Research demonstrates that slight changes in molecular structure, which varies among beta glucan sources, can significantly affect biological activity. All of our research is conducted with our ingredients at efficacious servings that are consistent with our recommended serving levels for product formulation and daily consumption.
Biothera’s superior intellectual property and dominant patent position provides customers with confidence in the safety, efficacy and long-term availability of the company’s products. Biothera has more than 40 U.S. patents and patents pending, with additional filings in more than 20 countries that protect matter of composition, manufacturing processes and applications.
Biothera has successfully defended its patents in U.S. courts against infringement. The company intends to continue to vigorously protect its intellectual property rights.